Skip to main content
Julie Desrosiers patent lawyer in Montreal

Julie Desrosiers

Partner Fasken
A new more effective and balanced patent linkage system will ensure that results are predictable and final for the pharmaceutical industry and generic drug manufacturers.
Jurisdiction Québec, 1991
Language(s) French, English
Office(s) Montréal
Contact
Share
  • LinkedIn

Overview

Julie Desrosiers practices intellectual property litigation. Julie regularly acts on behalf of high-tech corporations and advises clients on injunctions, seizures and proceedings to protect their intellectual property, trade secrets and strategic information.

Julie’s practice is currently focused almost exclusively on patent litigation. A seasoned litigator, she has been involved in several important patent infringement cases in the pharmaceutical sector. She appeared before the Supreme Court of Canada on behalf of the International Federation of Intellectual Property Attorneys and has served as counsel during various patent infringement cases ranging from helicopter landing gear to complex chemical molecules used to manufacture drugs. She has also acted in major copyright disputes resulting in precedent-setting decisions.

Widely sought for her opinion on issues concerning the patent linkage system, Julie often delivers seminars on patent litigation and is recognized for her experience by Chambers, the Canadian Legal Lexpert Directory and IAM Patent 1000.  She was recently listed in IP STARS Top 250 Women in IP and was named a Fellow of the American College of Trial Lawyers, a designation awarded only to the best litigators who have also demonstrated very highest standards of trial advocacy, ethical conduct, integrity, professionalism and collegiality.

Chambers Canada mention that Julie "is respected for her impressive ability in international patent litigation.

Julie is a member of the board of directors of the firm.

Achievements

  • Recognized in the Canadian Legal Lexpert Directory in Intellectual Property and Litigation - Intellectual Property, Lexpert 2025 to 2026
  • Recognized in Québec as a Litigation Star, Benchmark Litigation Canada 2024 to 2026
  • Recognized in Biotechnology and Life Sciences Practice in Montreal, The Best Lawyers in Canada 2022 to 2026
  • Recognized as a Thomson Reuters Stand-out Lawyer (formerly known as Acritas Star™ lawyer), Thomson Reuters stand-out lawyers 2022 to 2026
  • Recognized nationwide as a Leading Individual in Intellectual Property, The Legal 500 Canada 2021 to 2026
  • Recognized nationwide in Intellectual Property: Litigation, Chambers Canada 2018 to 2026
  • Recognized in the Canadian Legal Lexpert Directory in Life Sciences & Health, Lexpert 2022 to 2026
  • Recognized in Intellectual Property Law in Montreal, The Best Lawyers in Canada 2015 to 2026
  • Recognized by IAM Patent 1000 in Litigation, IAM Patent 1000 2025
  • Recognized in IP STARS as one of the Top 250 Women in IP, and as a Patent Star in Canada, IP Stars 2022 to 2025

Experience

  • Québec Court of Appeal confirms unconstitutionality of certain amendments to the Patented Medicines Regulations which govern the PMPRB federal patented drug pricing regime, [Case - Merck and al.], Fasken successfully represented a coalition of major pharmaceutical companies before the Quebec Superior Court and Quebec Court of Appeal to confirm the unconstitutionality and invalidity of certain amendments to the Patented Medicines Regulations which govern the PMPRB federal patented drug pricing regime.
  • Equisoft Sues For Breach Of Commercial Secrets In Front Of The Quebec Superior Court, [Case - Equisoft Inc.], Equisoft files a lawsuit against Protégez-vous for breach of commercial secrets.
  • Constitutional challenge in the Superior Court of Québec attacking controversial amendments to the Patented Medicines Regulations and the validity of the existing PMPRB regime under the Patent Act, [Case - Merck Canada Inc., Janssen Inc., Servier Canada Inc., Boehringer Ingelheim Canada Ltd/Ltée, Bayer Canada Inc., Theratechnologies Inc., and an additional (Confidential) pharmaceutical company], Constitutional challenge in the Superior Court of Québec.
  • Janssen overturns Court of Appeal ruling to exclude Remicade from Quebec's list of medications, [Case - Janssen Inc.], On January 16, 2019, the Quebec Court of Appeal declared invalid the decision of the Minister of Health and Social Services that Remicade, a Janssen product, had been removed from the Quebec ‘s List of Medications covered by the provincial drug plan. In 2017, the Minister of Health and Social S...
  • Interlocutory injunction against LaDose.pro and LaDose.ca, [Case - Applicants], We represented the applicants in an application for an interlocutory injunction against LaDose.pro and LaDose.ca. We obtained this injunction ordering two media monitoring websites to stop using or reproducing the copyrighted work belonging to the applicants.   This decision confirms the fact ...
  • FICPI represented at Supreme Court hearing regarding “Promise Doctrine”, [Case - International Federation of Intellectual Property Attorneys (FICPI)], AstraZeneca holds patent 2,139,653 (patent “653”), which claims the optically pure salts of esomeprazole, a proton pump inhibitor used in the reduction of gastric acid, in particular reflux esophagitis. Apotex applied to the federal Minister of Health for a Notice of Compliance, allowing it to se...
  • The Supreme Court rejects the “promise of the patent” doctrine and redefines the utility requirement for inventions patented in Canada, [Deal - International Federation of Intellectual Property Attorneys (FICPI)], AstraZeneca holds patent 2,139,653 (patent “653”), which claims the optically pure salts of esomeprazole, a proton pump inhibitor used in the reduction of gastric acid, in particular reflux esophagitis. Apotex applied to the federal Minister of Health for a Notice of Compliance, allowing it to se...
  • AstraZeneca v. Apotex and FICPI - esomeprazole patent SCC patent infringement, [Case - Confidential Client], On november 8 2016, the Supreme Court of Canada heard oral arguments in AstraZeneca v Apotex and reserved its decision in a case that raises the propriety of the Canadian Federal Courts' "promise doctrine."‎ Throughout the arguments, Fasken Martineau made submissions saying how the promise doctr...
  • Apotex Inc. v. H. Lundbeck A/S, [Case - Lundbeck], Action instituted by Apotex seeking a declaration of invalidity of Canadian patent no. 1,339,452 covering escitalopram on the grounds of anticipation, obviousness, inutility and insufficient disclosure. During this case : Lundbkeck answered with a counterclaim in infringement of the patent;...

Career & Education

Education

  • LLB, BCL University of Montreal

Memberships & Affiliations

  • Fellow of the American College of Trial Lawyers

Knowledge

  • New PMPRB Discussion Guide Sets Out Patented Medicine Price Review Framework, 7/4/2024
  • Federal Court Adopts IPIC’s Proposed Test for the Patentability of Computer-Implemented Inventions, 6/27/2022
  • Breaking PMPRB News: Another Win for Patients and the Innovative Pharmaceutical Industry, 4/19/2022
  • Experimental use is not disclosure for purposes of anticipation, 1/18/2021
  • Federal Court identifies loophole in Canadian Patent Act, 1/11/2021
  • Supreme Court Rejects the “Promise of the Patent”, Redefines Canada’s Patent Utility Requirement, 7/4/2017
  • Bill 96 Resource Centre | Reform to the Charter of the French language, An Act respecting French, the official and common language of Québec: Final Phase Coming Into Force on June 1, 2025 Adopted and assented to in 2022, An Act respecting French, the official and common language of Québec, commonly known as Bill 96, represents a major reform of Québec’s linguistic fr...

Events

  • Savez-vous garder un secret? La cybersécurité et les secrets commerciaux, enjeux pour l’entreprise d’aujourd’hui, 1/20/2021
  • Injonctions interlocutoires en propriété intellectuelle : du mythe à la réalité, 11/14/2018
  • Cross-border Aspects of Intellectual Property Disputes, 11/30/2016
  • Montréal Fasken Martineau Symposium (4th Edition), 5/8/2012

News

  • Thirteen Fasken lawyers recognized as IP Stars by Managing Intellectual Property, 8/4/2021
  • Several publications quote Julie Desrosiers and Patricia Hénault in relation to a copyright lawsuit, 4/28/2021
  • Droit-inc.com quotes Julie Desrosiers in an article on trade secrets, 4/13/2021
  • Julie Desrosiers Admitted to American College of Trial Lawyers, 3/11/2021
  • Fourteen Fasken lawyers recognized as IP Stars by Managing Intellectual Property, 6/22/2020
  • Fasken Partner Julie Desrosiers Recognized in the 2020 Edition of IP Stars Top 250 Women in IP, 6/22/2020
  • IAM Patent 1000 highlights Fasken Lawyers and Agents, 6/19/2020
  • Fasken Lawyers and Agents Recognized in IAM Patent 1000 and IAM Strategy 300, 6/28/2019
  • Fasken’s Julie Desrosiers recognized in the 2019 edition of IP Stars Top 250 Women in IP, 6/6/2019
  • Fasken Celebrates International Women’s Day 2019, 3/8/2019

Publications

  • Secrets commerciaux de tiers : la protection passe aussi par vos employés (Available in French only), 5/11/2021
  • Canada and EU Comprehensive Economic and Trade Agreement (CETA) reached in principle: What is the impact on pharmaceutical patents?, 11/1/2013
  • The law of trade secrets in Quebec and in Canada: A pragmatic approach, 8/15/2008
  • Implied Licence Exists for Copyrights, 2/19/2007
  • Intellectual Property Year in Review 2006, 1/1/2007
Article Canada and EU Comprehensive Economic and Trade Agreement (CETA) reached in principle: What is the impact on pharmaceutical patents?
Article The law of trade secrets in Quebec and in Canada: A pragmatic approach

Speaking Engagements

  • Business Issues: Future Outlook, 4/28/2015
  • CETA Issues: Canadian and Non-Canadian Pharmaceutical IP Regimes Comparison, 11/26/2013
  • Too much? Too little? Just right& Increased scrutiny of the description and the Goldilocks syndrome, 9/26/2013
  • Objections and Undertakings: What everyone should know about them, 5/17/2012
  • Compensation for copyright infringement, 5/1/2012
  • Fasken Martineau Training Day Program, 12/5/2011
  • Employeur ou employé : à qui attribuer la paternité de l'invention en l'absence d'un test d'ADN?, 11/16/2008
  • Trade secrets in Quebec, 8/19/2008
  • Patents: Ten pitfalls to avoid, 11/28/2006
Business Issues: Future Outlook Plenary - 7th Fasken Martineau Symposium location location Montreal
CETA Issues: Canadian and Non-Canadian Pharmaceutical IP Regimes Comparison Comprehensive Economic and Trade Agreement (CETA) Information Seminar